Navin Fluorine to meet analysts/investors on Nov 19, reports strong Q2/H1 FY26 results and significant capex
Navin Fluorine will hold an analyst/investor meet on Nov 19. The company reported robust Q2/H1 FY26 results with strong growth in sales and EBITDA, and announced significant capex for HFC and MPP capacity expansion.
The impact is high due to the strong financial results, which significantly exceed previous performance, and the announcement of substantial capex projects. These investments are expected to drive considerable revenue potential and future growth, fundamentally affecting the company's operational capacity and market position.
The announcement reports significant year-on-year growth in sales, EBITDA, and PBT for both Q2 and H1 FY26, indicating strong financial performance. Additionally, the company's substantial capital expenditure plans for HFC and MPP capacity expansion, along with positive outlooks for its business segments and new orders, suggest future growth and a positive business trajectory.
Navin Fluorine International Limited will be interacting with Analysts/Institutional Investors on November 19, 2025. The discussions will be based on publicly available information, including an enclosed presentation. The company reported strong financial performance for Q2 and H1 FY26 (Consolidated): * Q2 FY26 Sales: ₹758.4 crore, up 46% year-on-year and 5% quarter-on-quarter. * Q2 FY26 Operating EBITDA: ₹246.2 crore, a 129% year-on-year increase, with a margin of 32.5%. * H1 FY26 Sales: ₹1483.8 crore, up 42% year-on-year. * H1 FY26 Operating EBITDA: ₹453.0 crore, up 118% year-on-year, with a margin of 30.5%.
Key business highlights and capex announcements: * Capex for HFC capacity: An additional capacity equivalent to up to 15,000 MTPA of R32 with an investment of ₹236.5 crore, expected to be commissioned by Q3 FY27, with a peak revenue potential of ~₹600-825 crore per annum. * Capex for MPP de-bottlenecking at Dahej: An investment of ₹75 crore to support a new molecule for a global innovator, targeted for commissioning by Q3 FY27, with a peak revenue potential of ~₹140-160 crore per annum. * HPP Segment: Revenue growth of 38% in Q2 FY26, with AHF capex commissioning by Q3 FY26. * Specialty Chemicals Segment: Revenue growth of 39% in Q2 FY26, with the Chemours project on track for completion in Q1 FY27 and the Fluorospecialty plant contributing meaningfully. * CDMO Segment: Revenue growth of 98% in Q2 FY26, backed by a strong order book pipeline until FY27 and validation batches starting for a European CDMO MSA, with supplies targeted by January 2026.
What to do with a filing like this
Navin Fluorine International Limited filed this with the NSE as a statutory disclosure, categorised under investor meet intimation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Navin Fluorine International Limited. Read the original for the full detail.